Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma
https://doi.org/10.21518/2079-701X-2013-11-38-43
Abstract
OBJECTIVE. This study evaluated the effects of ebastine on serum eosinophil cationic protein (ECP) levels in patients with bronchial asthma. PATIENTS. Twenty patients with bronchial asthma and low efficiency of current therapy (11 patients with atopic disease and 9 with non-atopic disease) were enrolled in the study. METHODS. In an open-label design, all patients received ebastine 10 mg/day for 4 weeks and serum ECP levels, peripheral blood eosinophil counts, morning peak expiratory flow rate (PEFR) and thresholds for airway hyper-responsiveness (Dmin in asthgraphy) were determined before and after treatment. RESULTS. Serum ECP levels and peripheral blood eosinophil counts were significantly decreased. No significant change was found in the non-atopic patients, while the serum ECP level was significantly (p<0,001) decreased in the atopic patients. Furthermore, no significant change in Dmin was found, but PEFR was significantly (p<0,019) increased in the atopic type. CONCLUSION. Ebastine not only inhibits type I allergic reactions, but may also inhibit airway inflammation by reducing serum ECP levels, particularly in patients with atopic bronchial asthma.
About the Authors
T. Horiguchi
Department of Respiratory Diseases, Second Hospital for Medical Education, Fujita Health University of Medicine
Russian Federation
Russian Federation
S. Tachikawa
Department of Respiratory Diseases, Second Hospital for Medical Education, Fujita Health University of Medicine
Russian Federation
Russian Federation
J. . Kasahara
Department of Respiratory Diseases, Second Hospital for Medical Education, Fujita Health University of Medicine
Russian Federation
Russian Federation
Y. . Sasaki
Department of Respiratory Diseases, Second Hospital for Medical Education, Fujita Health University of Medicine
Russian Federation
Russian Federation
M. . Hirose
Department of Respiratory Diseases, Second Hospital for Medical Education, Fujita Health University of Medicine
Russian Federation
Russian Federation
M. . Shiga
Department of Respiratory Diseases, Second Hospital for Medical Education, Fujita Health University of Medicine
Russian Federation
Russian Federation
R. Kondo
Department of Respiratory Diseases, Second Hospital for Medical Education, Fujita Health University of Medicine
Russian Federation
Russian Federation
J. Miyazaki
Department of Respiratory Diseases, Second Hospital for Medical Education, Fujita Health University of Medicine
Russian Federation
Russian Federation
M. . Sugiyama
Department of Respiratory Diseases, Second Hospital for Medical Education, Fujita Health University of Medicine
Russian Federation
Russian Federation
References
1. Wiseman L.R., Faulds D. Ebastine // Drugs. 1996. №51. Р. 260–277.
2. Data on file at Dainippon Pharmaceutical Co. Ltd.
3. NIH International Consensus Report on Diagnosis and Management of Asthma. Publication No.92–3091. Bethesda, Md.
4. Motojima S., Frigas E., Loegering D.A. et al. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro // Am. Rev. Respir. Dis. 1989. №139 (3). Р. 801–805.
5. Suzuki H., Akizawa T., Narushima M. et al. A study of the specific gravity and electron microscopic picture of eosinophils and serum eosinophil cationic protein (ECP) // Allergy Pract. 1991. №11. Р. 61–65.
6. Gleich G.J., Flavahan N.A., Fujisawa T. et al. The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperactivity // J. Allergy Clin. Immunol. 1988. №81. Р. 776–781.
7. Japanese Society of Allergology, Diagnosis and Treatment of Adult Asthma // Makino S. Life Science Medica, 1995.
8. Venge P., Dahl R., Fredens K. et al. Epithelial injury by human eosinophils // Am. Rev. Respir. Dis. 1988. №138. S54–57.
9. Gleich G.J., Dahl R., Peterson C.G. et al. The eosinophil and bronchial asthma. Current understanding // J. Allergy Clin. Immunol. 1990. №85. Р. 422–436.
10. Kay A.B. Eosinophils as effector cells in immunity and hypersensitivity disorders // Clin. Exp. Immunol. 1985. №62. Р. 1–12.
11. Baba S., Sakakura Y., Baha K. et al. Clinical trial of LAS-90 on perennial allergic rhinitis: a double blind study in comparison with ketotifen fumarate // Rinsho Iyaku. 1994. №10. Р. 1143–1162.
Review
For citations:
Horiguchi T, Tachikawa S, Kasahara J, Sasaki Y, Hirose M, Shiga M, Kondo R, Miyazaki J, Sugiyama M. Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma. Meditsinskiy sovet = Medical Council. 2013;(11):38-43. (In Russ.) https://doi.org/10.21518/2079-701X-2013-11-38-43
Views:
481
Email this article 